Interview with University of Washington Professor and Dean Sheds Light on Reimbursing Novel Cell and Gene Therapies

The Evidence Base interviewed the University of Washington’s Sean Sullivan on the intricacies of reimbursement for novel therapies. Although these cell and gene therapies are designed to be curative, their clinical benefits are not always clear.

In this feature, following his participation in a workshop at the International Society for Pharmacoeconomics and Outcomes Research’s 2020 Asia Pacific meeting (Virtual ISPOR Asia Pacific 2020; 14–16 September), Sean Sullivan (University of Washington, WA, USA) discusses payment approaches that could potentially help better manage the market entry of innovative and potentially curative therapies, despite uncertainties surrounding their long-term benefits.” Read more here.

(Source: Sean Sullivan, The Evidence Base, 12/2/20)